Vascular, diabetes surge ahead at Abbott:
This article was originally published in Clinica
Executive Summary
Abbott Laboratories reported a 14.4% increase in sales of medical products in the fourth quarter, with its vascular devices and diabetes care units providing much of the impetus. The company did not disclose total medical product sales, but said diabetes care was up by 71% to $242m in the quarter, helped by the purchase of TheraSense. Vascular device sales rose by 12% to $60m. Fourth-quarter diagnostic sales rose by 15% to $927m. Group sales rose by 16% to $5.7bn, with earnings up 3% to $975m. Full-year sales and earnings were $20bn (+14%) and $3.2bn (+18%), respectively.